BioDrugs

, Volume 25, Issue 2, pp 89–103

Tacrolimus in the Treatment of Ocular Diseases

Authors

  • Jiajie Zhai
    • State Key Laboratory of OphthalmologyZhongshan Ophthalmic Center, Sun Yat-sen University
    • Institute of Ophthalmology and Visual Sciences of Guangdong Province
  • Jianjun Gu
    • State Key Laboratory of OphthalmologyZhongshan Ophthalmic Center, Sun Yat-sen University
    • State Key Laboratory of OphthalmologyZhongshan Ophthalmic Center, Sun Yat-sen University
    • State Key Laboratory of OphthalmologyZhongshan Ophthalmic Center, Sun Yat-sen University
Review Article

DOI: 10.2165/11587010-000000000-00000

Cite this article as:
Zhai, J., Gu, J., Yuan, J. et al. BioDrugs (2011) 25: 89. doi:10.2165/11587010-000000000-00000

Abstract

Tacrolimus (FK506) has been used successfully as a systemic immunomodulator for more than 2 decades, and numerous studies have investigated its mechanisms of action. Systemic and topical tacrolimus have been investigated as treatments for ocular surface disorders that may have an immune-based inflammatory component. In these studies, tacrolimus has shown efficacy in corneal graft rejection, inflammatory conjunctival and corneal diseases, uveitis, and graft-versus-host disease. As these disorders are often refractory to other available treatments, ophthalmic or systemic tacrolimus is a welcome nontoxic adjunct or replacement to potentially toxic topical or systemic immunosuppressive therapies.

Copyright information

© Adis Data Information BV 2011